Skip to main content
ENTA
NASDAQ Life Sciences

Enanta Posts $23.7M Q4 Loss, Cuts Workforce by a Third, Cash Through Fiscal 2029

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$10.41
Mkt Cap
$310.768M
52W Low
$10.05
52W High
$17.15
52W Position info
3.6% above low
Off High info
39% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

ENTA is trading near its 52-week low of $10.05 (3.6% above the low).

Summary

Enanta reported a $23.7M fiscal Q4 loss on $12.9M of royalty revenue and disclosed a roughly one-third workforce cut, with $194.5M in cash funding operations into fiscal 2029. Zelicapavir pediatric topline is expected in 1Q 2027.


Key Events · Earnings and Guidance · ENTA

  • Fiscal Q4 Loss Widens to $23.7M

    Net loss was $23.7M, or $0.81 per diluted share, on revenue of $12.9M versus $18.7M ($0.87) on $15.1M a year earlier. Full-year net loss was $68.2M, or $2.35 per share, versus $81.9M ($3.84) in fiscal 2025.

  • Workforce Cut by Roughly One-Third

    A September 2026 strategic review led to targeted workforce reductions of approximately one-third of employees, focusing resources on priority programs and extending financial flexibility.

  • Cash Runway Into Fiscal 2029

    Cash, cash equivalents and marketable securities totaled $194.5M at September 30, 2026, which the company says funds operations into fiscal 2029 alongside its retained royalty revenue.

  • Immunology Timelines Slip Into 2027

    EDP-978 Phase 1 topline data is now expected in 1Q 2027, and the EDP-903 STAT6 IND is now targeted for 2Q 2027 due to a drug manufacturing delay. EPS-5336 was selected as the MRGPRX2 development candidate with an IND targeted for 4Q 2027.


Analysis · ENTA · Life Sciences

The balance sheet is the story here: $194.5M in cash and securities, plus retained royalties, funds operations into fiscal 2029. That runway explains the September move to cut roughly one-third of the workforce, and it also frames the two immunology milestones pushed into 2027 — EDP-978 Phase 1 data and the EDP-903 IND, the latter now set for 2Q 2027 on a manufacturing delay. For the quarter, Enanta posted a $23.7M loss and a $68.2M full-year loss. Revenue remains entirely AbbVie's MAVYRET royalty stream, which fell to $12.9M from $15.1M a year ago, and 54.5% of that cash royalty goes to OMERS through 2032. Near-term value hinges on zelicapavir: LOTUS pediatric topline is due 1Q 2027 and RESOLVE Phase 2b data in 2027.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ENTA was trading at $10.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $310.8M. The 52-week trading range was $10.05 to $17.15. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ENTA - Latest Insights

ENTA
Nov 16, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $10.66
Real-time Price: $11.20 info
Change: +$0.540 (+5%) info
Market Cap: $310.768M info
ENTA
Oct 29, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.15
Real-time Price: $11.20 info
Change: +$0.050 (+0.45%) info
Market Cap: $310.768M info
ENTA
Oct 28, 2026, 7:14 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $11.99
Real-time Price: $11.20 info
Change: -$0.790 (-7%) info
Market Cap: $310.768M info
ENTA
Aug 12, 2026, 7:00 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $13.52
Real-time Price: $11.20 info
Change: -$2.32 (-17%) info
Market Cap: $310.768M info
ENTA
Aug 10, 2026, 4:01 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $13.81
Real-time Price: $11.20 info
Change: -$2.61 (-19%) info
Market Cap: $310.768M info